JNJ — Johnson & Johnson

Johnson & Johnson Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales: Q2 2026 worldwide sales reached $25.3 billion, a 5.6% operational increase year-over-year, despite a 460 basis point headwind from STELARA. Excluding STELARA, sales grew double digits.
• Net Earnings: Reported net earnings were $5.5 billion, with diluted earnings per share (EPS) at $2.27, slightly down from $2.29 a year ago.
• Adjusted Earnings: Adjusted net earnings were $7.1 billion, with adjusted diluted EPS at $2.90, reflecting a 5.7% increase.
• Innovative Medicine Sales: Sales of $16.4 billion, up 6.8%, with strong contributions from oncology and immunology.
• MedTech Sales: Sales totaled $8.9 billion, growing 3.6%, with notable growth in vision and surgery but slower performance in cardiovascular.

2. Strategic Updates and Business Highlights

• Product Launches: Successful launches of ICOTYDE, INLEXZO, and RYBREVANT, with ICOTYDE showing strong early uptake (over 10,000 patients initiated therapy).
• Oncology Leadership: J&J aims to be the leading oncology company by 2030, with DARZALEX and CARVYKTI showing significant sales growth.
• MedTech Innovations: Continued advancements in cardiovascular technology, including the launch of CARTOSOUND SONATA and the upcoming OTTAVA robotic surgical system.
• Acquisitions: Plans to acquire Firefly Bio to enhance oncology pipeline; expected to close in Q3 2026.

3. Forward Guidance and Outlook

• Sales Growth: Full-year operational sales growth guidance raised to 6.5%-7.1%, with a midpoint of $100.6 billion. Reported sales growth expected at 7.0%-7.6%.
• EPS Guidance: Adjusted operational EPS guidance increased to $11.50-$11.65, representing a 7.3% year-on-year growth.
• Long-term Growth: Confidence in achieving double-digit growth by the end of the decade, supported by a robust pipeline and strategic investments.

4. Bad News, Challenges, or Points of Concern

• STELARA Decline: Significant decline in STELARA sales by 55.7% due to biosimilar competition and market dynamics.
• MedTech Performance: Cardiovascular segment underperformed, with growth impacted by physician selectivity and recent clinical trial results affecting Impella usage.
• Cost Pressures: Increased selling, marketing, and administrative expenses due to investments in new product launches; litigation and restructuring costs also elevated.
• Market Conditions: Potential headwinds from macroeconomic factors and currency fluctuations, with a negative foreign currency impact estimated at $100 million.

5. Notable Q&A Insights

• Sales Guidance Breakdown: CFO Joe Wolk indicated that the increase in sales guidance reflects stronger pharmaceutical growth, partially offset by tempered expectations in MedTech, particularly in the Abiomed business.
• ICOTYDE Launch Success: Jennifer Taubert highlighted the rapid uptake of ICOTYDE, with over 18,000 prescriptions written and strong prescriber engagement.
• Abiomed Concerns: Tim Schmid addressed concerns regarding the Abiomed business, emphasizing that the slowdown is temporary and driven by physician caution rather than structural issues.
• Milvexian Trials: Confidence in the milvexian program remains high, with expectations for significant market opportunities pending trial results.

Overall, Johnson & Johnson reported a strong quarter with robust growth in key areas, despite facing challenges in certain segments and external pressures. The company remains optimistic about its future growth trajectory and strategic initiatives.